Praxis Precision Medicines to Participate in Upcoming Investor Conferences BOSTON, May 17, 2024 (GLOBE NEWSWIRE) -- , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will be participating in three upcoming conferences. Praxis management will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference, taking place in New York, NY at the NASDAQ...
Nature’s Miracle and Agrify Corporation Announces Signing of the Definitive Merger Agreement Transaction Expected to Close in the Second Half of 2024 ONTARIO, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- Nature's Miracle Holding Inc. (NASDAQ: NMHI; NMHIW) (“Nature’s Miracle” or the “Company”), a leader in vertical farming technology and infrastructure, and Agrify Corporation (NASDAQ: AGFY) (“Agrify”), announced today that both parties have signed a definitive agreement and plan of merger (“Agreement”) in which a new wholly-owned subsidiary of Nature’s Miracle will merge with and into Agrify...
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results Plans to initiate two efficacy studies investigating PRAX-628 in focal onset seizures in the second half of 2024 and first half of 2025, respectively Continued strong recruitment for the pivotal Essential3 trials in Essential Tremor (ET), with over 50,000 pre-screening forms and over 7,000 referrals received to date that meet pre-qualifying eligibility criteria; topline results expected in the second half of 2024 Randomization in PRAX-562 Phase 2 EMBOLD study completed in pediatric pati...
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024 ― Entered into a collaboration and ex-U.S. license agreement with Sanofi for the development and commercialization of losmapimod ― ― On track to report topline data for Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) in the fourth quarter of 2024 ― ― Industry veteran, Patrick Horn M.D., Ph.D., appointed as chief medical officer ― ― Conference call and webcast scheduled for 8:00 a.m. ET today ― CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Fulcr...
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy ― Sanofi receives exclusive rights to commercialize losmapimod in all territories outside the U.S.; Fulcrum retains full U.S. commercialization rights ― ― Fulcrum will receive an upfront payment of $80.0 million, and is eligible to receive $975.0 million in potential milestones, plus royalties on ex-U.S. product sales; parties will share future global development costs 50:50 ― ― Conference call and webc...
NVIDIA Grace Hopper Ignites New Era of AI Supercomputing From Climate and Weather to Scientific Exploration, Switzerland’s Alps Supercomputer, France’s EXA1-HE Supercomputer and Others to Deliver 200 Exaflops of AI for Groundbreaking Research Using Energy-Efficient Grace-Based Systems HAMBURG, Germany, May 12, 2024 (GLOBE NEWSWIRE) -- ISC—Driving a fundamental shift in the high-performance computing industry toward AI-powered systems, NVIDIA today announced nine new supercomputers worldwide are using to speed scientific research and discovery. Combined, the systems deliver 200 exaflops...
NVIDIA Accelerates Quantum Computing Centers Worldwide With CUDA-Q Platform Supercomputers in Germany, Japan and Poland Incorporate Grace-Hopper and Quantum-Classical Accelerated Supercomputing Platform to Advance Quantum Computing Research HAMBURG, Germany, May 12, 2024 (GLOBE NEWSWIRE) -- ISC -- NVIDIA today announced that it will accelerate quantum computing efforts at national supercomputing centers around the world with the open-source . Supercomputing sites in Germany, Japan and Poland will use the platform to power the (QPUs) inside their NVIDIA-accelerated high-performance...
Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024 BOSTON, May 10, 2024 (GLOBE NEWSWIRE) -- , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will report financial results for the first quarter 2024 on Monday, May 13, 2024, before the U.S. financial markets open. About Praxis Praxis Precision Medicines is a clinical-stage biopharmaceutical...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.